Browsing Tag
Parkinson’s disease
11 posts
Why targeting ERK and NF-κB pathways may change Parkinson’s disease drug development
Discover how BioVie Inc. is targeting ERK and NF-κB pathways in Parkinson’s disease and what Phase 2 data could mean. Read the full analysis.
Why CNS drug developers are paying attention to Alamar Biosciences’ latest move
How Alamar Biosciences’ Neuro 220 Panel could reshape CNS biomarker discovery and drug trials. Explore the strategic implications now.
How the Nautilus Biotechnology and Michael J. Fox Foundation alliance signals a shift in Parkinson’s biomarker strategy (NASDAQ: NAUT)
Find out how Nautilus Biotechnology’s Parkinson’s collaboration signals a strategic shift in biomarker platforms and what it means for investors and drug developers.
Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases
Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field.
Breakthrough Parkinson’s research: Annovis says buntanetap improved cognition in patients with amyloid co-pathology
Discover why new biomarker data suggests amyloid co-pathology may accelerate cognitive decline in Parkinson’s and how buntanetap could help change treatment planning.
Jupiter Neurosciences secures FDA green light for Phase 2a clinical trial of JOTROL in Parkinson’s disease
Find out how Jupiter Neurosciences’ FDA-approved JOTROL Phase 2a trial could reshape Parkinson’s treatment and redefine the biotech innovation race.
AbbVie seeks FDA approval for tavapadon to improve motor control in Parkinson’s disease patients
AbbVie (NYSE: ABBV) files FDA application for tavapadon, a once-daily oral Parkinson’s treatment aiming to improve motor control and expand its neuroscience pipeline.
How does kavach (mucuna pruriens) help in parkinsonism and what makes its natural levodopa content medically significant?
Learn how kavach (Mucuna pruriens), a natural source of levodopa, supports Parkinson’s treatment and why it remains vital in modern neurology.
Why is the brain–computer interface market growing so fast—and what does it mean for healthcare?
Discover how brain–computer interfaces may reshape mental health, education, and neurodegenerative treatment – read the latest insights now!
BioArctic advances exidavnemab phase 2a cohorts after safety review
BioArctic expands its Phase 2a trial for exidavnemab after a successful safety review. Read how this impacts Parkinson’s and MSA drug development today.